



Pharmacokinetics of Factor VIII in Patients with Hemophilia A in Relation to Clinical and Radiological Outcomes

Thesis

Submitted for Partial Fulfillment of Master
Degree in Pediatrics

By

Mohamed Gomaa Khalil

M.B., B, Ch, Faculty of Medicine Ain Shams University, 2014

Under Supervision of

Prof. Dr. Azza Abd Elgawad Tantawy

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Prof. Dr. Iman Ahmed Ragab

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا أنك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the
Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound
gratitude to **Prof. Dr. Azza Abd Elgawad Tantawy**,
Professor of Pediatrics Faculty of Medicine - Ain Shams
University for her keen guidance, kind supervision, valuable
advice and continuous encouragement, which made possible
the completion of this work.*

*I am also delighted to express my deepest gratitude and
thanks to **Prof. Dr. Iman Ahmed Ragab**, Professor of
Pediatrics Faculty of Medicine - Ain Shams University, for her
kind care, continuous supervision, valuable instructions,
constant help and great assistance throughout this work.*

Mohamed Gomaa

List of Contents

Title	Page No.
List of Tables	i
List of Figures	v
List of Abbreviations	vii
Introduction	1
Aim of the Work.....	3
Review of Literature	
▪ Classification and Pathophysiology	4
▪ Genetics	7
▪ Clinical Manifestations	11
▪ Laboratory Evaluation of Hemophilia	16
▪ Management of Hemophilia.....	23
▪ Pharmacokinetics of Factor VIII	39
Patients and Methods	50
Results	60
Discussion	95
Summary	104
Conclusion.....	108
References	109
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Degree of severity in Hemophilia.....	6
Table (2):	Frequency of different types of mutations reported in F8 and F9.....	7
Table (3):	Genetic and non-genetic Factors influencing the development of inhibitors in hemophilia A Patients.....	9
Table (4):	Comparison of one-stage and chromogenic fviii and fix activity assays	21
Table (5):	Available FVIII products	26
Table (6):	Suggested plasma factor peak level and duration of administration (when there is no significant resource constraint).....	32
Table (7):	PK parameters used in the study of coagulation factors	42
Table (8):	Typical PK values of FVIII in adult HA patient.....	46
Table (9):	Clinical Joint Score of patients with hemophilia (ref) for both knees, ankles, elbows.....	52
Table (10):	Functional Independence Score for Haemophilia (FISH) Reference/table.....	53
Table (11):	Plain X-Ray score of joints for patients with hemophilia A for Ankles, Knees, Elbows.	54
Table (12):	Magnetic Resonance Imaging (MRI) score of joints for patients with hemophilia A	55
Table (13):	Explains basis of MRI scoring based on soft tissue changes and osteo-chondral changes	56
Table (14):	Ultrasound score of joints (Knees, Ankles) for patients with hemophilia A.....	57
Table (15):	Social status of studied patients.	60

List of Tables Cont...

Table No.	Title	Page No.
Table (16):	Description of diseases diagnosis and status of patients with Hemophilia A.....	61
Table (17):	Description of Clinical joints scores and FISH score of patients.	62
Table (18):	Description of X-ray scores of patients.....	63
Table (19):	Description of MRI Score of patients.	65
Table (20):	Description of ultrasound score of patients.....	67
Table (21):	Description of trough and peak factor VIII levels and dose received of factor VIII in patients.....	68
Table (22):	Comparison between groups with different trough level of factor VIII according to sociodemographic data of studied patients.....	71
Table (23):	Comparison between groups with different trough level of factor VIII according to diagnosis, disease status of patients with Hemophilia A.....	72
Table (24):	Comparison between groups with different trough level of factor VIII according to prophylactic dose received.....	73
Table (25):	Comparison between groups with different trough level of factor VIII according to clinical joint score and FISH score of patients.....	74
Table (26):	Comparison between groups with different trough level of factor VIII according to MRI scores of patients	76
Table (27):	Comparison between groups with different trough level of factor VIII according to ultrasound scores of patients	77

List of Tables Cont...

Table No.	Title	Page No.
Table (28):	Comparison between groups with different trough level of factor VIII according to Sociodemographic data of studied patients.	79
Table (29):	Comparison between groups with different trough level of factor VIII according to diagnosis, disease status of patients with Hemophilia A.....	79
Table (30):	Comparison between groups with different trough level of factor VIII according to prophylactic dose received.....	81
Table (31):	Comparison between groups with different trough level of factor VIII according to Clinical joint score and FISH score of patients.....	82
Table (32):	Comparison between groups with different trough level of factor VIII according to MRI scores of patients.	84
Table (33):	Comparison between groups with different trough level of factor VIII according to ultrasound scores of patients.....	85
Table (34):	Comparison between the two groups according to Sociodemographic data of studied patients.	86
Table (35):	Comparison between the two groups according to diagnosis, disease status of patients with Hemophilia A.....	87
Table (36):	Comparison between the two groups according to prophylactic dose received.	88
Table (37):	Comparison between the two groups according to clinical joint score and FISH score of patients	88
Table (38):	Comparison between the two groups according to X-ray scores of patients.	90

List of Tables Cont...

Table No.	Title	Page No.
Table (39):	Comparison between the two groups according to MRI and ultrasound scores of patients.....	91
Table (40):	Comparison between the two groups according to peak and trough factor VIII levels of patients.	92
Table (41):	Correlation between trough level of factor VIII and clinical assessment scores of patients.....	92
Table (42):	Correlation between trough level of factor VIII and radiological assessment scores of patients. ...	93
Table (43):	Correlation between trough level of factor VIII and prophylactic dose and peak level of factor VIII one hour after receiving the dose.	93
Table (44):	Correlation between peak level of factor VIII and clinical assessment scores of patients	94
Table (45):	Correlation between trough level of factor VIII and radiological assessment scores of patients. ...	94

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Clotting cascade.....	5
Figure (2):	One-stage APTT-based factor activity assay principle	18
Figure (3):	Shows the reaction of the two-stage chromogenic substrate assays.....	20
Figure (4):	Shows secretion and activation of coagulation factor VIII.....	40
Figure (5):	Shows activation of factor VIII to active form VIIIa — the figure shows specific cleavage sites recognized by thrombin during activation process, FIXa and FXa binding sites and FVIII activation inhibitor, active protein C (APC)-binding sites.....	41
Figure (6):	The <i>in vivo</i> behavior of infused FVIII concentrate	43
Figure (7):	Shows the plasma disappearance pattern of FVIII	45
Figure (8):	Plain P-A x-ray of a studied patient with score of 3 showing irregular subchondral margins with narrowing of joint space but still >1 mm, erosions of joint margins, no osteoporosis, enlarged epiphysis, subchondral cyst formation.	64
Figure (9):	Plain P-A x-ray of a studied patient with score of 12 with presence of osteoporosis, enlarged epiphysis, narrowing of joint space, irregular subchondral surface with subchondral cyst formation and erosion of joint margins.	64

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (10):	MRI cuts of studied patient with MRI score of 1 with only presence of small joint effusion with no synovial hypertrophy, hemosiderin nor presence of surface joint erosions nor cartilage degradation.....	65
Figure (11):	MRI cuts of a studied patient with MRI score of 8 with presence of moderate joint effusion and synovial hypertrophy and hemosiderin with presence of surface joint erosions and cartilage degradation.	66
Figure (12):	Ultrasound knee of a studied patient with score of 5 with presence of moderate effusion with synovial hypertrophy and subchondral damage and cartilage damage.	67
Figure (13):	Ultrasound knee of a studied patient with score of 2 with presence of moderate effusion with no synovial hypertrophy, subchondral damage nor cartilage damage.	68
Figure (14):	Trend chart described the relation between trough and peak levels of factor VIII	69
Figure (15):	Pie chart classifying the patients according to trough level.	70
Figure (16):	Pie chart classifying the patients according to trough level.	78
Figure (17):	Showing the difference between the two groups as regards FISH score	89
Figure (18):	Boxplot showing the relation between the two group as regards the worst individual joint score.	89

List of Abbreviations

Abb.	Full term
ADH	Antidiuretic hormone
APC	Active protein C
APTT	Activated partial thromboplastin time
ASA	Acetylsalicylic acid
AUC	Area under curve
BDD FVIII	B-domain-deleted FVIII
BDD	B-domain-deleted
BSA	Bovine serum albumin
BU	Bethesda units
CFC	Coagulation factor concentrates
CL	Clearance
CSAs	Chromogenic substrate assays
CT	Computed tomography
DDAVP	Desmopressin (1-deamino-8-D-arginine vasopressin)
EACA	Epsilon aminocaproic acid
ECAT	External quality Control of diagnostic Assays and Tests
EHL	Extended half-life
FDA	Food and Drug Administration
FFP	Fresh frozen plasma
FISH	Functional Independence Score for Hemophilia
FIX	Factor IX
FVIII	Factor VIII
FVIIIa	Activated FVIII
FX	Factor X
FXa	Activated FX
FXIa	Activated FXI

List of Abbreviations Cont...

Abb.	Full term
HEK.....	Human embryonic kidney
Ig.....	Immunoglobulin
IU.....	International units
IVR.....	In-vivo recovery
MR.....	Magnetic resonance
MRT.....	Mean residence time
NONMEM.....	Nonlinear mixed effects modeling
NSAIDs.....	Non-steroidal anti-inflammatory drugs
OSAs.....	One stage Assays
PD.....	Pharmacodynamics
PEG.....	Polyethylene glycol
PK.....	Pharmacokinetics
PT.....	Prothrombin time
PTT.....	Partial thromboplastin time
rFVIII.....	Recombinant factor VIII
r-FVIII.....	Recombinant FVIII
rFVIII-Fc.....	Antihemophilic factor (recombinant), Fc fusion protein
rFVIII-FS.....	Recombinant FVIII formulated with sucrose
rFVIII-SC.....	Antihemophilic factor (recombinant), single chain
SC.....	Single chain
US FDA.....	US Food and Drug Administration
VD.....	Volume of distribution
VWF.....	Von Willebrand factor
Vss.....	Volume of distribution at Steady State

INTRODUCTION

Hemophilia is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) (in hemophilia A) or factor IX (FIX) (in hemophilia B) (**White et al., 2001**). Estimations based on the WFH's annual global surveys indicate that the number of people with hemophilia in the world is approximately 400,000 (**Stonebraker et al., 2010**).

Prophylaxis is the treatment by intravenous injection of factor concentrate in order to prevent anticipated bleeding. Prophylaxis was conceived from the observation that moderate hemophilia patients with clotting factor level >1 IU/dl seldom experience spontaneous bleeding and have much better preservation of joints function. According to a review of 6 randomized controlled trials, preventive therapy started early in childhood, as compared with on-demand treatment, can reduce total bleeds and bleeding into joints, resulting in decreased overall joint deterioration and improved quality of life (**Feldman et al., 2006; Gringeri et al., 2011**).

However, the optimal dosing and infusion frequency to reduce bleed risk and enable participation in routine daily and physical activities is debated. (**Fischer et al., 2013**)

The benefit of pharmacokinetics (PK) -guided dosing is that both prophylactic and “on demand” dosing will be based on actual FVIII trough and peak levels instead of current FVIII estimates based on body weight and in-vivo recovery (IVR)

based dosing. Moreover, PK-guidance will optimize dosing as knowledge will increase with regard to the relationship between FVIII level and bleeding in individual patients. In addition, an increase in dosing will not only depends on actual bleeding and a reduction of dosing can be considered by the treating professional in consultation with patients and parents. However, the dose and frequency of factor VIII for patients on prophylaxis should only be reduced if clinically justified and impact should be monitored with regard to bleeding events, bleeding pattern and joint status (**Berntorp et al., 2017**).

We believe that PK-guided dosing as the alternative to body weight and IVR-based dosing will play an important role in further individualization of therapy.

AIM OF THE WORK

To assess the trough and peak level of factor VIII in patients with hemophilia A on low dose prophylaxis and to study its impact on the clinical and radiological joint status.